Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

NCT00075582 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00075582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00075582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
September 4, 2004
Completion date
September 30, 2021
Enrollment
390 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

adult rhabdomyosarcoma, embryonal childhood rhabdomyosarcoma, embryonal-botryoid childhood rhabdomyosarcoma, previously untreated childhood rhabdomyosarcoma